SWAV - Shockwave Medical Inc Stock Price, Fair Value and News

330.45USD-0.04 (-0.01%)Market Closed

Market Summary

USD330.45-0.04

Market Closed

-0.01%

SWAV Alerts

Big jump in Revenue (Y/Y)

Big jump in Earnings (Y/Y)

SWAV Stock Price

View Fullscreen

SWAV RSI Chart

SWAV Valuation

Market Cap

12.4B

Price/Earnings (Trailing)

75.89

Price/Sales (Trailing)

15.75

EV/EBITDA

62.87

Price/Free Cashflow

74.68

SWAV Price/Sales (Trailing)

SWAV Profitability

EBT Margin

23.29%

Return on Equity

21.75%

Return on Assets

9.95%

Free Cashflow Yield

1.34%

SWAV Fundamentals

SWAV Revenue

Revenue (TTM)

788.0M

Rev. Growth (Yr)

35.85%

Rev. Growth (Qtr)

7.8%

SWAV Earnings

Earnings (TTM)

163.5M

Earnings Growth (Yr)

41.46%

Earnings Growth (Qtr)

24.92%

Breaking Down SWAV Revenue

Last 7 days

0.1%

Last 30 days

1.3%

Last 90 days

39.8%

Trailing 12 Months

20.3%

How does SWAV drawdown profile look like?

SWAV Financial Health

Current Ratio

13.81

Debt/Equity

0.97

Debt/Cashflow

0.27

SWAV Investor Care

Shares Dilution (1Y)

2.50%

Diluted EPS (TTM)

4.26

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	788.0M	0	0	0
2023	557.2M	616.6M	671.3M	730.2M
2022	298.9M	363.7M	429.9M	489.7M
2021	84.5M	130.1M	175.7M	237.1M
2020	50.9M	51.1M	59.4M	67.8M
2019	18.2M	25.9M	33.7M	42.9M
2018	4.4M	7.0M	9.6M	12.3M
2017	0	0	0	1.7M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Shockwave Medical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	godshall douglas evan	sold (taxes)	-377,303	329	-1,144	president & ceo
May 02, 2024	phung trinh	sold (taxes)	-108,178	329	-328	vp, finance
May 02, 2024	zacharias isaac	sold (taxes)	-174,799	329	-530	president, cco
Mar 26, 2024	francis laura	sold	-450,000	300	-1,500	-
Mar 26, 2024	francis laura	acquired	9,882	6.588	1,500	-
Mar 26, 2024	zacharias isaac	sold	-1,150,680	287	-4,000	president, cco
Mar 26, 2024	francis laura	gifted	-	-	-1,500	-
Mar 26, 2024	francis laura	gifted	-	-	1,500	-
Mar 11, 2024	zacharias isaac	sold (taxes)	-138,633	250	-554	president, cco
Mar 06, 2024	phung trinh	sold	-5,315	253	-21.00	vp, finance

Which funds bought or sold SWAV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-0.43	27,988,000	67,890,000	0.09%
May 07, 2024	Williams Jones Wealth Management, LLC.	added	3.47	1,900,420	4,374,840	0.06%
May 07, 2024	ASSETMARK, INC	added	28.92	5,561,550	10,184,700	0.03%
May 07, 2024	Lisanti Capital Growth, LLC	new	-	1,149,470	1,149,470	0.28%
May 07, 2024	TimesSquare Capital Management, LLC	reduced	-3.92	28,214,000	72,173,000	1.05%
May 07, 2024	ClariVest Asset Management LLC	reduced	-27.8	435,813	2,300,250	0.24%
May 07, 2024	OPPENHEIMER ASSET MANAGEMENT INC.	added	0.7	333,351	795,840	0.01%
May 07, 2024	Swiss National Bank	added	0.41	9,890,260	23,705,900	0.02%
May 07, 2024	Qsemble Capital Management, LP	new	-	722,573	722,573	0.16%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	73.11	2,282,440	3,448,100	-%

Are Funds Buying or Selling SWAV?

Are funds buying SWAV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SWAV

No. of Funds

Unveiling Shockwave Medical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.85%	3,633,720	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	wellington management group llp	6.78%	2,500,594	SC 13G
Jan 24, 2024	blackrock inc.	10.1%	3,740,596	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	2.8%	1,012,393	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Jan 23, 2023	blackrock inc.	12.7%	4,572,659	SC 13G/A
Jan 10, 2023	vanguard group inc	10.22%	3,694,931	SC 13G/A
Jul 08, 2022	blackrock inc.	12.1%	4,313,553	SC 13G
Feb 14, 2022	price t rowe associates inc /md/	8.7%	3,077,252	SC 13G/A

Recent SEC filings of Shockwave Medical Inc

View All Filings

Date Filed	Form Type	Document
May 06, 2024	10-Q	Quarterly Report
May 06, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
Apr 29, 2024	DEFM14A	DEFM14A
Apr 26, 2024	10-K/A	Annual Report
Apr 18, 2024	PREM14A	PREM14A
Apr 09, 2024	8-K	Current Report
Apr 05, 2024	8-K	Current Report

Peers (Alternatives to Shockwave Medical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.6B	40.3B	-4.60%	-4.35%	32.45	4.53	-2.84%	-3.08%
BDX	67.4B	19.7B	-3.65%	-5.69%	50.6	3.42	4.82%	-17.56%
ALGN	20.6B	3.9B	-9.77%	-6.38%	44.54	5.26	5.72%	46.72%
BAX	18.2B	14.9B	-15.25%	-20.81%	6.88	1.22	2.98%	207.68%
MID-CAP
ATR	10.0B	3.5B	5.58%	23.16%	31.94	2.82	6.16%	35.06%
HSIC	9.3B	12.5B	-1.81%	-10.76%	24.01	0.75	-0.61%	-18.83%
BIO	7.8B	2.7B	-13.87%	-26.12%	-12.29	2.93	-4.68%	82.43%
XRAY	5.8B	3.9B	-12.53%	-31.61%	-61.76	1.47	0.23%	91.03%
AXNX	3.4B	387.1M	-0.62%	22.51%	-215.56	8.87	30.82%	65.57%
PDCO	2.3B	6.6B	-0.84%	-0.80%	11.98	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.97%	-19.30%	-1.85	0.4	7.94%	-1661.78%
ANIK	423.5M	166.7M	10.85%	9.31%	-5.12	2.54	6.67%	-456.34%
ANGO	236.7M	324.0M	-12.80%	-31.58%	-1.23	0.73	-3.19%	-337.41%
APYX	48.8M	52.3M	-6.00%	-59.48%	-2.61	0.93	17.61%	19.28%
AEMD	3.4M	3.7M	-25.71%	271.43%	-0.27	0.89	5.77%	8.23%

Shockwave Medical Inc News

Latest updates

Shockwave Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	7.8%	219	203	186	180	161	144	131	121	94.00	84.00	65.00	56.00	32.00	23.00	20.00	10.00	15.00	14.00	11.00	10.00	7.00
Gross Profit	7.3%	191	178	162	156	140	127	113	104	81.00	72.00	54.00	46.00	24.00	16.00	14.00	7.00	10.00	9.00	7.00	6.00	4.00
Costs and Expenses	10.3%	148	134	118	123	100	84.00	77.00	74.00	65.00	58.00	51.00	46.00	41.00	32.00	27.00	25.00	29.00	13.00	24.00	21.00	19.00
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	27.00	25.00	29.00	-	20.00	17.00	16.00
S&GA Expenses	10.9%	74.00	67.00	57.00	57.00	54.00	43.00	42.00	41.00	36.00	33.00	28.00	26.00	24.00	16.00	14.00	11.00	10.00	10.00	8.00	7.00	6.00
R&D Expenses	5.1%	44.00	42.00	40.00	37.00	27.00	24.00	20.00	21.00	17.00	15.00	14.00	12.00	10.00	9.00	8.00	8.00	12.00	10.00	8.00	7.00	7.00
EBITDA Margin	-1.1%	0.26*	0.26*	0.26*	0.26*	0.28*	0.26*	0.22*	0.17*	0.11*	-0.02*	-0.19*	-0.38*	-	-	-	-	-	-	-	-	-
Interest Expenses	-0.2%	3.00	3.00	3.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income Taxes	-147.4%	-5.30	11.00	10.00	4.00	2.00	-96.26	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Earnings Before Taxes	-9.8%	50.00	55.00	45.00	33.00	41.00	45.00	35.00	26.00	15.00	13.00	2.00	-0.35	-23.56	-15.87	-12.90	-18.10	-18.75	-14.73	-12.93	-10.59	-12.79
EBT Margin	-2.4%	0.23*	0.24*	0.24*	0.25*	0.26*	0.25*	0.21*	0.15*	0.10*	-0.04*	-0.21*	-0.40*	-	-	-	-	-	-	-	-	-
Net Income	24.9%	55.00	44.00	35.00	29.00	39.00	141	35.00	26.00	15.00	13.00	2.00	-0.42	-23.60	-15.87	-12.93	-18.12	-18.77	-14.74	-12.96	-10.61	-12.80
Net Income Margin	2.9%	0.21*	0.20*	0.36*	0.40*	0.43*	0.44*	0.20*	0.15*	0.10*	-0.04*	-0.22*	-0.41*	-	-	-	-	-	-	-	-	-
Free Cashflow	-56.8%	27.00	64.00	44.00	31.00	27.00	41.00	27.00	25.00	-1.35	18.00	6.00	-0.52	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	4.9%	1,644	1,567	1,474	787	783	646	476	417	373	346	299	276	269	272	281	287	221	232	138	147	158
Current Assets	4.1%	1,275	1,225	1,129	456	591	459	395	352	310	286	256	240	233	246	258	264	198	217	131	141	152
Cash Equivalents	-13.8%	283	328	498	141	281	157	128	100	66.00	91.00	93.00	86.00	58.00	52.00	215	218	123	140	39.00	42.00	138
Inventory	3.4%	111	108	97.00	92.00	83.00	75.00	69.00	60.00	53.00	43.00	39.00	36.00	34.00	30.00	29.00	23.00	16.00	12.00	9.00	8.00	7.00
Net PPE	14.2%	79.00	69.00	62.00	60.00	54.00	48.00	39.00	32.00	28.00	24.00	23.00	21.00	20.00	16.00	13.00	13.00	13.00	5.00	4.00	3.00	3.00
Goodwill	0%	40.00	40.00	40.00	40.00	40.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	-0.7%	892	898	873	170	213	135	120	112	105	104	79.00	68.00	65.00	46.00	44.00	42.00	43.00	39.00	30.00	27.00	28.00
Current Liabilities	-11.4%	92.00	104	78.00	80.00	142	63.00	54.00	66.00	51.00	52.00	40.00	36.00	33.00	26.00	21.00	18.00	19.00	24.00	19.00	15.00	15.00
Long Term Debt	0.1%	733	732	731	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	6.00	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	732	731	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	12.4%	752	669	601	617	571	511	356	305	268	242	220	208	204	226	237	245	178	193	108	119	129
Retained Earnings	50.1%	166	110	66.00	31.00	2.00	-36.81	-177	-212	-238	-252	-265	-267	-267	-243	-227	-214	-196	-177	-163	-150	-139
Additional Paid-In Capital	5.0%	586	558	535	586	569	549	535	519	507	495	486	476	471	469	465	460	374	371	271	270	269
Shares Outstanding	0.8%	37.00	37.00	37.00	37.00	36.00	36.00	36.00	36.00	36.00	35.00	-	34,914	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	7,700	-	-	-	-	-	-	-	3,700	-	-	-	4,200	-	-	-	1,000	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-50.0%	35,840	71,703	50,651	39,737	33,962	52,436	34,488	28,871	1,937	20,831	9,322	2,186	-17,303	-12,399	-16,430	-18,166	-24,189	-12,570	-10,604	-10,518	-14,415
Share Based Compensation	5.2%	22,937	21,811	18,410	17,046	15,967	12,643	11,732	11,005	9,510	8,208	7,387	6,523	5,139	3,242	2,846	2,391	1,871	1,310	1,106	818	412
Cashflow From Investing	65.1%	-84,453	-242,262	-305,879	-83,768	6,182	-35,276	-5,276	5,816	-27,414	-23,102	-4,782	27,214	27,086	-153,607	12,106	29,703	4,325	16,791	7,641	-83,555	-420
Cashflow From Financing	3155.5%	5,011	-164	612,997	-95,841	83,409	9,596	383	500	2,520	500	2,387	-2,138	-3,200	1,173	1,284	83,648	3,930	96,372	491	-2,067	113,256

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SWAV Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Product revenue	$ 218,805	$ 161,066
Cost of revenue:
Cost of product revenue	28,207	21,066
Gross profit	190,598	140,000
Operating expenses:
Research and development	44,466	26,971
Sales and marketing	74,492	54,011
General and administrative	29,233	19,204
Total operating expenses	148,191	100,186
Income from operations	42,407	39,814
Income (loss) from equity method investment	713	(823)
Interest and Other Income	12,318	1,740
Interest expense	(2,943)	(636)
Other (expense) income, net	(2,496)	642
Net income before taxes	49,999	40,737
Income tax expense	(5,347)	1,612
Net income	55,346	39,125
Other comprehensive income (loss):
Unrealized (loss) gain on available-for-sale securities, net of tax	(402)	505
Net gain reclassified from accumulated other comprehensive income	0	(5)
Total comprehensive income	$ 54,944	$ 39,625
Net income per share
Basic (USD per share)	$ 1.48	$ 1.07
Diluted (USD per share)	$ 1.44	$ 1.03
Denominator:
Basic (in shares)	37,284,946	36,427,263
Diluted (in shares)	38,472,013	37,979,448
Type of Revenue [Extensible List]	Product [Member]	Product [Member]
Type of Cost, Good Or Service [Extensible List]	Product [Member]	Product [Member]

SWAV Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 281,674	$ 328,422
Short-term investments	747,559	662,132
Accounts receivable, net	124,440	114,552
Inventory	111,215	107,587
Prepaid expenses and other current assets	10,462	12,567
Total current assets	1,275,350	1,225,260
Operating lease right-of-use assets	34,919	29,707
Property and equipment, net	78,693	68,923
Equity method investment	2,356	1,643
Intangible assets, net	91,960	92,857
Goodwill	39,568	39,568
Deferred tax assets	111,900	99,169
Other assets	9,001	9,436
TOTAL ASSETS	1,643,747	1,566,563
CURRENT LIABILITIES:
Accounts payable	9,843	8,868
Accrued liabilities	78,838	91,696
Lease liability, current portion	3,653	3,641
Total current liabilities	92,334	104,205
Lease liability, noncurrent portion	40,336	35,103
Convertible Debt, Noncurrent	732,810	731,863
Related party contract liability, noncurrent portion	12,273	12,273
Deferred tax liabilities	3,609	3,609
Other liabilities	7,659	9,307
TOTAL LIABILITIES	891,990	897,886
STOCKHOLDERS’ EQUITY:
Preferred stock	0	0
Common stock	38	37
Additional paid-in capital	586,017	557,882
Accumulated other comprehensive (loss) income	(109)	293
Retained earnings	165,811	110,465
TOTAL STOCKHOLDERS’ EQUITY	751,757	668,677
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	1,643,747	1,566,563
Long-Term Income Tax Liability	$ 2,969	$ 1,526

About Shockwave Medical Inc

ShockWave Medical, Inc., a medical device company, develops intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters for use in our IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter for use in IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

CEO	Mr. Douglas E. Godshall M.B.A.
WEBSITE	https://shockwavemedical.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	1001

Shockwave Medical Inc Frequently Asked Questions

What is the ticker symbol for Shockwave Medical Inc? What does SWAV stand for in stocks?

SWAV is the stock ticker symbol of Shockwave Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Shockwave Medical Inc (SWAV)?

As of Tue May 07 2024, market cap of Shockwave Medical Inc is 12.41 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SWAV stock?

You can check SWAV's fair value in chart for subscribers.

What is the fair value of SWAV stock?

You can check SWAV's fair value in chart for subscribers. The fair value of Shockwave Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Shockwave Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SWAV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Shockwave Medical Inc a good stock to buy?

The fair value guage provides a quick view whether SWAV is over valued or under valued. Whether Shockwave Medical Inc is cheap or expensive depends on the assumptions which impact Shockwave Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SWAV.

What is Shockwave Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, SWAV's PE ratio (Price to Earnings) is 75.89 and Price to Sales (PS) ratio is 15.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SWAV PE ratio will change depending on the future growth rate expectations of investors.